The backbone of progress – preclinical studies and innovations with zoledronic acid
Jonathan R. Green, Andreas Guenther
20110101
2011 Feb 1
Crit Rev Oncol Hematol
The backbone of progress – preclinical studies and innovations with zoledronic acid
Crit Rev Oncol Hematol. 2011 Feb;77, Jonathan R. Green, Andreas Guenther
Abstract
Abstract
Bisphosphonates (BPs) are antiresorptive agents that block pathologic bone resorption by inhibiting osteoclast function and later inducing osteoclast apoptosis. These agents localize to bone and break the vicious cycle of bone resorption that results from cross-stimulation between cancer cells and the bone remodeling cells, thereby reducing cancer-induced osteolysis and the tumor burden in bone. Thus nitrogen-containing BPs (N-BPs) have well established clinical benefits in the treatment of bone...
